AR069002A1 - Compuestos de fenilpirrolidina, sus usos para la preparacion de medicamentos y sus usos para el tratamiento de alteraciones melatoninergicas, y composiciones farmaceuticas que los comprende - Google Patents

Compuestos de fenilpirrolidina, sus usos para la preparacion de medicamentos y sus usos para el tratamiento de alteraciones melatoninergicas, y composiciones farmaceuticas que los comprende

Info

Publication number
AR069002A1
AR069002A1 ARP080104616A ARP080104616A AR069002A1 AR 069002 A1 AR069002 A1 AR 069002A1 AR P080104616 A ARP080104616 A AR P080104616A AR P080104616 A ARP080104616 A AR P080104616A AR 069002 A1 AR069002 A1 AR 069002A1
Authority
AR
Argentina
Prior art keywords
phenyl
pyrrolidin
methoxy
disorders
butyramide
Prior art date
Application number
ARP080104616A
Other languages
English (en)
Spanish (es)
Inventor
Guglietta Antonio
Lluis Falco Joseph
Palomer Albert
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of AR069002A1 publication Critical patent/AR069002A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP080104616A 2007-10-25 2008-10-23 Compuestos de fenilpirrolidina, sus usos para la preparacion de medicamentos y sus usos para el tratamiento de alteraciones melatoninergicas, y composiciones farmaceuticas que los comprende AR069002A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200702800A ES2331276B1 (es) 2007-10-25 2007-10-25 Compuestos de fenilpirrolidina.

Publications (1)

Publication Number Publication Date
AR069002A1 true AR069002A1 (es) 2009-12-23

Family

ID=40291255

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104616A AR069002A1 (es) 2007-10-25 2008-10-23 Compuestos de fenilpirrolidina, sus usos para la preparacion de medicamentos y sus usos para el tratamiento de alteraciones melatoninergicas, y composiciones farmaceuticas que los comprende

Country Status (21)

Country Link
US (1) US20120184594A1 (cg-RX-API-DMAC7.html)
EP (1) EP2203422B1 (cg-RX-API-DMAC7.html)
JP (1) JP2011500764A (cg-RX-API-DMAC7.html)
KR (1) KR20100072287A (cg-RX-API-DMAC7.html)
CN (1) CN101878198A (cg-RX-API-DMAC7.html)
AR (1) AR069002A1 (cg-RX-API-DMAC7.html)
AT (1) ATE513809T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008316473A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0817660A2 (cg-RX-API-DMAC7.html)
CA (1) CA2703458A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008003141A1 (cg-RX-API-DMAC7.html)
DK (1) DK2203422T3 (cg-RX-API-DMAC7.html)
ES (2) ES2331276B1 (cg-RX-API-DMAC7.html)
MX (1) MX2010004469A (cg-RX-API-DMAC7.html)
PL (1) PL2203422T3 (cg-RX-API-DMAC7.html)
PT (1) PT2203422E (cg-RX-API-DMAC7.html)
RU (1) RU2010120845A (cg-RX-API-DMAC7.html)
SI (1) SI2203422T1 (cg-RX-API-DMAC7.html)
TW (1) TW200920353A (cg-RX-API-DMAC7.html)
UY (1) UY31425A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009053441A1 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753709A (en) * 1995-06-07 1998-05-19 Bristol-Myers Squibb Company N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
PT1189900E (pt) * 1999-06-30 2004-05-31 Bristol Myers Squibb Co Derivados de aminopirrolidina heterociclicos utilizados como agentes melatonergicos

Also Published As

Publication number Publication date
BRPI0817660A2 (pt) 2015-09-29
PT2203422E (pt) 2011-09-26
TW200920353A (en) 2009-05-16
CN101878198A (zh) 2010-11-03
JP2011500764A (ja) 2011-01-06
UY31425A1 (es) 2009-04-30
CA2703458A1 (en) 2009-04-30
SI2203422T1 (sl) 2011-10-28
EP2203422B1 (en) 2011-06-22
PL2203422T3 (pl) 2011-11-30
AU2008316473A1 (en) 2009-04-30
DK2203422T3 (da) 2011-10-10
MX2010004469A (es) 2010-07-06
ES2331276A1 (es) 2009-12-28
RU2010120845A (ru) 2011-11-27
ES2368697T3 (es) 2011-11-21
WO2009053441A1 (en) 2009-04-30
CL2008003141A1 (es) 2009-03-06
KR20100072287A (ko) 2010-06-30
US20120184594A1 (en) 2012-07-19
ATE513809T1 (de) 2011-07-15
ES2331276B1 (es) 2010-10-21
EP2203422A1 (en) 2010-07-07

Similar Documents

Publication Publication Date Title
CL2012001501A1 (es) Co-cristal constituido por agomelatina y un acido organico que presenta un estado solido a temperatura ambiente; procedimientos de preparacion; composicion farmaceutica; y uso en el tratamiento de trastornos del sistema melatoninergico tales como estres, trastornos del sueño y trastornos de ansiedad generalizada, entre otros.
HRP20170095T1 (hr) Novi kristalni oblik iii agomelatina, postupak za njegovu pripravu i farmaceutski pripravci istog
AR071253A1 (es) Forma cristalina vi de la agomelatina, su procedimiento de preparacion y las scomposiciones farmaceuticas que la contienen
AR059206A1 (es) Uso de derivados de 4-imidazol para trastornos del snc
ME02024B (me) Makrociklična jedinjenja hinoksalina kao inhibitori hcv ns3 proteaze
NZ573565A (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
PY0622198A (es) Nueva forma cristalina IV de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que la contienen
PY0622199A (es) Forma cristalina V de agomelatina, procedimiento para su preparación, composiciones farmacéuticas que lo contienen y su utilización en el tratamiento de trastornos melatoninérgicos
CL2011002231A1 (es) Forma cristalina vi de la agomelatina; proceso de preparacion; composicion farmaceutica; y su uso para tratar estres, ansiedad, trastornos del sueño, enfermedades cardiovasculares, esquizofrenia, fobia, depresion, enfermedades del sistema digestivo.
ECSP088876A (es) Formas de polimorfos de la (2s)-(4e)-n-metil-5-(3-isopropoxipiridin)il]-4-penten-2-amina para el tratamiento de desórdenes del sistema nervioso central
AR098599A2 (es) Procedimiento de utilización de una composición farmacéutica que comprende derivados de carboestirilo e inhibidores de la reabsorción de serotonina para preparar un medicamento para el tratamiento de trastornos del animo
NI200700084A (es) Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento del trastorno de ansiedad generalizada
HRP20100263T1 (hr) Ciklopropil amini kao modulatori histaminskog h3 receptora
RU2015146305A (ru) Галактоолигосахаридная композиция и ее применение для предотвращения или лечения когнитивной дисфункции и эмоциональных расстройств при психоневрологических заболеваниях или старении
JP2015521642A5 (cg-RX-API-DMAC7.html)
US20260000641A1 (en) Isotopically enriched analogs of 5,6-methylenedioxy-2-aminoindane (imdai)
AR069003A1 (es) Compuestos de indolina, sus usos en la preparacion de medicamentos y sus usos para el tratamiento de alteraciones melatoninergicas, composiciones farmaceuticas que los comprende y uso de la composicion farmaceutica para preparar un medicamento
NO20084865L (no) Behandling av smertelidelser med trans 4-(3,4-diklorfenyl)-1, 2, 3,4-tetrahydro-1-nafthalenamin og dens formamid
CL2011000184A1 (es) Compuestos derivados de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno; agonista de receptores de melatonina; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a los compuestos; y su uso de los compuestos en la preparacion de medicamentos.
AR069004A1 (es) Compuestos de 2,3-dihidro-benzofurano sus usos para la preparacion de medicamentos y sus usos para el tratamiento de alteraciones melatoninergicas, y composiciones farmaceuticas que los comprende
PA8529801A1 (es) Un nuevo compuesto derivado de la triptamina y sus analogos
UY30529A1 (es) Compuestos de 1h-quinolin-4-ona, procedimientos, usos y composiciones
AR070951A1 (es) Compuestos de indano, sus usos para la preparacion de medicamentos y sus usos para el tratamiento de alteraciones melatoninergicas y composiciones farmaceuticas que los comprende
AR070003A1 (es) Derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
HRP20090632T1 (hr) Novi derivati naftalena, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže

Legal Events

Date Code Title Description
FA Abandonment or withdrawal